Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

British Journal of Haematology

Volumn 170, Issue 5, 2015, Pages 669-678

  Roberts, Andrew W ^a,b,c,d   Advani, Ranjana H ^e   Kahl, Brad S ^f   Persky, Daniel ^g   Sweetenham, John W ^h   Carney, Dennis A ^c,d,i   Yang, Jianning ^j   Busman, Todd B ^j   Enschede, Sari H ^j   Humerickhouse, Roderick A ^j   Seymour, John F ^c,d,i  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c VICTORIAN COMPREHENSIVE CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g UNIVERSITY OF ARIZONA   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

^j ABBVIE INC   (United States)

more..

Author keywords

B cell malignancy; BCL2; Navitoclax; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NAVITOCLAX; RITUXIMAB; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; SULFONAMIDE;

ADULT; AGED; AGGRESSIVE LYMPHOMA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRONCHITIS; CAMPYLOBACTER ENTERITIS; CD3+ T LYMPHOCYTE; CELLULITIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CYSTITIS; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR INFECTION; ESCHERICHIA COLI INFECTION; FATIGUE; FEMALE; FLATULENCE; FOLLICULAR LYMPHOMA; GASTROENTERITIS; GINGIVITIS; HEADACHE; HERPES LABIALIS; HERPES ZOSTER; HUMAN; HYPOKALEMIA; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; LABYRINTHITIS; LARGE CELL LYMPHOMA; LOWER RESPIRATORY TRACT INFECTION; LYMPHOBLASTOMA; LYMPHOCYTOMA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MOLLUSCUM CONTAGIOSUM; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEUTROPENIA; OPEN STUDY; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN INFECTION; THROMBOCYTOPENIA; THRUSH; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RITUXIMAB; SULFONAMIDES;

EID: 84938981686     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13487     Document Type: Article

References (32)

1. Adams, J.M. & Cory, S. (1998) The Bcl-2 protein family: arbiters of cell survival. Science, 281, 1322-1326.
2. Anderson, M.A., Huang, D. & Roberts, A. (2014) Targeting BCL2 for the treatment of lymphoid malignancies. Seminars in Hematology, 51, 219-227.
3. Berinstein, N.L., Grillo-Lopez, A.J., White, C.A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P. & Shen, D. (1998) Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology, 9, 995-1001.
4. Byrd, J.C., Kitada, S., Flinn, I.W., Aron, J.L., Pearson, M., Lucas, D. & Reed, J.C. (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 99, 1038-1043.
5. Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H. & Jaffe, E.S. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117, 5019-5032.
6. Cartron, G., Watier, H., Golay, J. & Solal-Celigny, P. (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood, 104, 2635-2642.
7. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
8. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
9. Foran, J.M., Rohatiner, A.Z., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. & Lister, T.A. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, 317-324.
10. Gandhi, L., Camidge, D.R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C.L., McKeegan, E.M., Litvinovich, E., Hemken, P.M., Dive, C., Enschede, S.H., Nolan, C., Chiu, Y.L., Busman, T., Xiong, H., Krivoshik, A.P., Humerickhouse, R., Shapiro, G.I. & Rudin, C.M. (2011) Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Journal of Clinical Oncology, 29, 909-916.
11. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J.; International Workshop on Chronic Lymphocytic Leukemia. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
12. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., vonGrunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. & Stilgenbauer, S.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
13. Hanahan, D. & Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
14. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
15. Iacona, I., Lazzarino, M., Avanzini, M.A., Rupolo, M., Arcaini, L., Astori, C., Lunghi, F., Orlandi, E., Morra, E., Zagonel, V. & Regazzi, M.B. (2000) Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Therapeutic Drug Monitoring, 22, 295-301.
16. Jazirehi, A.R., Vega, M.I. & Bonavida, B. (2007) Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Research, 67, 1270-1281.
17. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
18. Khaw, S.L., Merino, D., Anderson, M.A., Glaser, S.P., Bouillet, P., Roberts, A.W. & Huang, D.C. (2014) Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia, 28, 1207-1215.
19. Kitada, S., Pedersen, I.M., Schimmer, A.D. & Reed, J.C. (2002) Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene, 21, 3459-3474.
20. Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J.V., Dmoszynska, A., Raposo, J.C., Offner, F.C., Gomez-Codina, J., Belch, A., Cunningham, D., Wassner-Fritsch, E. & Stein, G. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology, 26, 4579-4586.
21. Mason, K.D., Carpinelli, M.R., Fletcher, J.I., Collinge, J.E., Hilton, A.A., Ellis, S., Kelly, P.N., Ekert, P.G., Metcalf, D., Roberts, A.W., Huang, D.C. & Kile, B.T. (2007) Programmed anuclear cell death delimits platelet life span. Cell, 128, 1173-1186.
22. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
23. Merino, D., Khaw, S.L., Glaser, S.P., Anderson, D.J., Belmont, L.D., Wong, C., Yue, P., Robati, M., Phipson, B., Fairlie, W.D., Lee, E.F., Campbell, K.J., Vandenberg, C.J., Cory, S., Roberts, A.W., Ludlam, M.J., Huang, D.C. & Bouillet, P. (2012) Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood, 119, 5807-5816.
24. Nguyen, D.T., Amess, J.A., Doughty, H., Hendry, L. & Diamond, L.W. (1999) IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. European Journal of Haematology, 62, 76-82.
25. Park, C.M., Bruncko, M., Adickes, J., Bauch, J., Ding, H., Kunzer, A., Marsh, K.C., Nimmer, P., Shoemaker, A.R., Song, X., Tahir, S.K., Tse, C., Wang, X., Wendt, M.D., Yang, X., Zhang, H., Fesik, S.W., Rosenberg, S.H. & Elmore, S.W. (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. Journal of Medicinal Chemistry, 51, 6902-6915.
26. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M.; MabThera International Trial Group. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379-391.
27. Roberts, A.W., Seymour, J.F., Brown, J.R., Wierda, W.G., Kipps, T.J., Khaw, S.L., Carney, D.A., He, S.Z., Huang, D.C., Xiong, H., Cui, Y., Busman, T.A., McKeegan, E.M., Krivoshik, A.P., Enschede, S.H. & Humerickhouse, R. (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. Journal of Clinical Oncology, 30, 488-496.
28. Rudin, C.M., Hann, C.L., Garon, E.B., Ribeiro de Oliveira, M., Bonomi, P.D., Camidge, D.R., Chu, Q., Giaccone, G., Khaira, D., Ramalingam, S.S., Ranson, M.R., Dive, C., McKeegan, E.M., Chyla, B.J., Dowell, B.L., Chakravartty, A., Nolan, C.E., Rudersdorf, N., Busman, T.A., Mabry, M.H., Krivoshik, A.P., Humerickhouse, R.A., Shapiro, G.I. & Gandhi, L. (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical Cancer Research, 18, 3163-3169.
29. Vaux, D.L., Cory, S. & Adams, J.M. (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature, 335, 440-442.
30. Wilson, W.H., O'Connor, O.A., Czuczman, M.S., LaCasce, A.S., Gerecitano, J.F., Leonard, J.P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.L., Cui, Y., Busman, T., Elmore, S.W., Rosenberg, S.H., Krivoshik, A.P., Enschede, S.H. & Humerickhouse, R.A. (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncology, 11, 1149-1159.
31. Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V. & Engert, A. (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood, 94, 2217-2224.
32. Wobser, M., Voigt, H., Eggert, A.O., Houben, R., Kauczok, C.S., Brocker, E.B. & Becker, J.C. (2007) Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. British Journal of Cancer, 96, 1540-1543.